Promising curcumin-based drug design: Mono-carbonyl analogues of curcumin (MACs)

Current Pharmaceutical Design

Volumn 19, Issue 11, 2013, Pages 2114-2135

  Zhao, Chengguang ^a   Liu, Zhiguo ^a   Liang, Guang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Anti inflammation; Anticancer; Curcumin; Drug desgin; Mono carbonyl analogue of curcumin; diketone moiety

Indexed keywords

CURCUMIN; MONOCARBONYL ANALOG OF CURCUMIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; DRUG DEGRADATION; DRUG DESIGN; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84875395775     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213805289282     Document Type: Review

References (142)

1. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as Curecumin: From kitchen to clinic. Biochem Pharmacol 2008; 75: 787-809.
2. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett 2008; 267: 133-164.
3. Kim JH, Gupta SC, Park B, Yadav VR, Aggarwal BB. Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)-αB and NF-αBαregulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis. Mol Nutr Food Res 2012; 56: 454-465.
4. Gupta SC, Sung B, Kim JH, et al. Multitargeting by turmeric, the golden spice: From kitchen to clinic. Mol Nutr Food Res 2012; DOI: 10.1002/mnfr.201100741.
5. Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 2008; 10: 511-546.
6. Gupta SC, Prasad S, Kim JH, et al. Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep 2011; 28: 1937-1955.
7. Kohli K, Ali J, Ansari M, Raheman Z. Curcumin: a natural antiinflammatory agent. Indian J Pharmacol 2005; 37: 141-147.
8. Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov Today 2012; 17: 71-80.
9. Esatbeyoglu T, Huebbe P, Ernst I, et al. Curcumin-From Molecule to Biological Function. Angew Chem Int Ed Engl 2012; 51: 5308-5332.
10. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4: 807-818.
11. Steward WP, Gescher AJ. Curcumin in cancer management: recent results of analogue design and clinical studies and desirable future research. Mol Nutr Food Res 2008; 52: 1005-1009.
12. Anand P, Thomas SG, Kunnumakkara AB, et al. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 2008; 76: 1590-1611.
13. Tønnesen HH, Karlsen J. Studies on curcumin and curcuminoids. Z Lebens Unters Forsch A 1985; 180: 402-404.
14. Wang YJ, Pan MH, Cheng AL, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 1997; 15: 1867-1876.
15. Rosemond M, St John-Williams L, Yamaguchi T, Fujishita T, Walsh J. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases. Chem Biol Interact 2004; 147: 129-139.
16. Grogan G. Emergent mechanistic diversity of enzyme-catalysed β-diketone cleavage. Biochem J 2005; 388: 721-730.
17. Agrawal DK, Mishra PK. Curcumin and its analogues: potential anticancer agents. Med Res Rev 2010; 30: 818-860.
18. Al-Hujaily EM, Mohamed AG, Al-Sharif I, et al. PAC, a novel curcumin analogue, has anti-breast cancer properties with higher efficiency on ER-negative cells. Breast Cancer Res Treat 2011; 128: 97-107.
19. Lin L, Liu Y, Li H, et al. Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030. Br J Cancer 2011; 105: 212-220.
20. Qiu X, Du Y, Lou B, et al. Synthesis and identification of new 4-arylidene curcumin analogues as potential anticancer agents targeting nuclear factor-αB signaling pathway. J Med Chem 2010;53 (23):8260-8273.
21. Lin L, Hutzen B, Zuo M, et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res 2010; 70(6):2445-2454.
22. Zhu S, Moore TW, Lin X, et al. Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts. Integr Biol (Camb) 2012; 4: 633-640.
23. Tierney BJ, McCann GA, Cohn DE, et al. HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells. Cancer Biol Ther 2012; 13: 766-775.
24. Liang G, Shao LL, Wang Y, et al. Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg Med Chem 2009; 17: 2623-2631.
25. Wang Y, Xiao J, Zhou H, et al. A novel mono-carbonyl analogue of curcumin,(1E, 4E)-1, 5-bis (2, 3-dimethoxyphenyl) penta-1, 4-dien-3-one, induced cancer cell H460 apoptosis via activation of endoplasmic reticulum stress signaling pathway. J Med Chem 2011; 54: 3768-3778.
26. Wang Y, Yu C, Pan Y, et al. A Novel Compound C12 Inhibits Inflammatory Cytokine Production and Protects from Inflammatory Injury In vivo. PLoS One 2011; 6: e24377.
27. Wu J, Li J, Cai Y, et al. Evaluation and Discovery of novel synthetic chalcone derivatives as anti-inflammatory agents. J Med Chem 2011; 54: 8110-8123.
28. Xiao J, Wang Y, Peng J, et al. A synthetic compound, 1, 5-bis (2-methoxyphenyl) penta-1, 4-dien-3-one (B63), induces apoptosis and activates endoplasmic reticulum stress in non-small cell lung cancer cells. Int J Cancer 2011; 131: 1455-1465.
29. Zhao C, Cai Y, He X, et al. Synthesis and anti-inflammatory evaluation of novel mono-carbonyl analogues of curcumin in LPSstimulated RAW 264.7 macrophages. Eur J Med Chem 2010; 45: 5773-5780.
30. Tonnesen HH, Karlsen J. Studies on curcumin and curcuminoids. 5. Alkaline degradation of curcumin. Z Lebensm Unter Forsch 1985; 180:132-134.
31. Tønnesen HH, Karlsen J, van Henegouwen GB. Studies on curcumin and curcuminoids VIII. Photochemical stability of curcumin. Z Lebensm Unter Forsch 1986; 183: 116-122.
32. Tønnesen HH, Greenhill J. Studies on curcumin and curcuminoids. XXII: Curcumin as a reducing agent and as a radical scavenger. Int J Pharm 1992; 87: 79-87.
33. Maing YI, Miller I. (1984) Curcumin-metal colour complexes and process for preparing them. EP Patent 0,025,637.
34. Todd P. Curcumin-Komplexe. Patentschrift DE 1991; 40: 118.
35. Tønnesen HH, Másson M, Loftsson T. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int J Pharm 2002; 244: 127-315.
36. Tomren M, Masson M, Loftsson T, Tønnesen HH. Studies on curcumin and curcuminoids:: XXXI. Symmetric and asymmetric curcuminoids: Stability, activity and complexation with cyclodextrin. Int J Pharm 2007; 338: 27-34.
37. Wang YJ, Pan MH, Cheng AL, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 1997; 15: 1867-1876.
38. Wahlström B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh) 1978; 43: 86-92.
39. Sharma RA, Ireson CR, Verschoyle RD, et al. Effects of Dietary Curcumin on Glutathione S-Transferase and Malondialdehyde-DNA Adducts in Rat Liver and Colon Mucosa. Clin Cancer Res 2001; 7: 1452-1458.
40. Ravindranath V, Chandrasekhara N. In vitro studies on the intestinal absorption of curcumin in rats. Toxicology 1981; 20: 251-257.
41. Ruffin M, Normolle D, Heath D, et al. Dose escalation of curcumin in healthy adults. Cancer Epidemiol Biomarkers Prev 2003; 12: 1324S.
42. Garcea G, Berry DP, Jones DJL, et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 2005; 14: 120-125.
43. Garcea G, Jones D, Singh R, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 2004; 90: 1011-1015.
44. Sharma RA, McLelland HR, Hill KA, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001; 7: 1894-1900.
45. Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin. Clin Cancer Res 2004; 10: 6847-6854.
46. Sharma RA, Steward WP, Gescher AJ. Pharmacokinetics and pharmacodynamics of curcumin. The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease. Adv Exp Med Biol 2007: 453-470.
47. Ravindranath V, Chandrasekhara N. Metabolism of curcumnstudies with [3H]curcumin. Toxicology 1982; 22: 337-344.
48. Holder GM, Plummer JL, Ryan AJ. The metabolism and excretion of curcumin (1, 7-bis-(4-hydroxy-3-methoxyphenyl)-1, 6-heptadiene-3, 5-dione) in the rat. Xenobiotica 1978; 8: 761-768.
49. Ireson C, Orr S, Jones DJL, et al. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 2001; 61: 1058-1064.
50. Ireson CR, Jones DJL, Orr S, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 2002; 11: 105-111.
51. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14: 4491-4499.
52. Carroll RE, Benya RV, Turgeon DK, et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila) 2011; 4: 354-364.
53. Baum L, Lam CWK, Cheung SKK, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 2008; 28: 110-113.
54. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res 2005; 2: 131-136.
55. Ellis EM. Microbial aldo-keto reductases. FEMS Microbiol Lett 2002; 216: 123-131.
56. Jin Y, Penning TM. Aldo-keto reductases and bioactivation/ detoxication.Annu Rev Pharmacol Toxicol 2007; 47: 263-292.
57. Jiao Y, Wilkinson IV J, Christine Pietsch E, et al. Iron chelation in the biological activity of curcumin. Free Radic Biol Med 2006; 40: 1152-1160.
58. Borsari M, Ferrari E, Grandi R, Saladini M. Curcuminoids as potential new iron-chelating agents: spectroscopic, polarographic and potentiometric study on their Fe (III) complexing ability. Inorganica Chim Acta 2002; 328: 61-68.
59. Mohammadi K, Thompson KH, Patrick BO, et al. Synthesis and characterization of dual function vanadyl, gallium and indium curcumin complexes for medicinal applications. J Inorg Biochem 2005; 99: 2217-2225.
60. Barik A, Mishra B, Kunwar A, et al. Comparative study of copper (II)-curcumin complexes as superoxide dismutase mimics and free radical scavengers. Eur J Med Chem 2007; 42: 431-439.
61. Bernabé-Pineda M, Rami{dotless}́rez-Silva MT, Romero-Romo MA, González-Vergara E, Rojas-Hernández A. Spectrophotometric and electrochemical determination of the formation constants of the complexes Curcumin-Fe (III)-water and Curcumin-Fe (II)-water. Spectrochim Acta Part A: Mol Biomol Spectrosc 2004; 60: 1103-1105.
62. Mei X, Luo X, Xu S, et al. Gastroprotective effects of a new zinc (II)-curcumin complex against pylorus-ligature-induced gastric ulcer in rats. Chem Biol Interact 2009; 181: 316-321.
63. Straganz GD, Glieder A, Brecker L, Ribbons DW, Steiner W. Acetylacetone-cleaving enzyme Dke1: a novel CC-bond-cleaving enzyme from Acinetobacter johnsonii. Biochem J 2003; 369: 573-581.
64. Leitgeb S, Straganz G, Nidetzky B. Biochemical characterization and mutational analysis of the mononuclear non-haem Fe2+ site in Dke1, a cupin-type dioxygenase from Acinetobacter johnsonii. Biochem J 2009; 418: 403-411.
65. Straganz GD, Hofer H, Steiner W, Nidetzky B. Electronic substituent effects on the cleavage specificity of a non-heme Fe2+-dependent α-diketone dioxygenase and their mechanistic implications. J Am Chem Soc 2004; 126: 12202-12203.
66. Rosemond M, St John-Williams L, Yamaguchi T, Fujishita T, Walsh JS. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases. Chem Biol Interact 2004; 147: 129-139.
67. Ahn BZ, Sok DE. Michael acceptors as a tool for anticancer drug design. Curr Pharm Des 1996; 2: 247-262.
68. Lin L, Shi Q, Nyarko AK, et al. Antitumor agents. 250. Design and synthesis of new curcumin analogues as potential anti-prostate cancer agents. J Med Chem 2006; 49: 3963-3972.
69. Somparn P, Phisalaphong C, Nakornchai S, Unchern S, Morales NP. Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. Biol Pharm Bull 2007; 30: 74-78.
70. Pan MH, Lin-Shiau SY, Lin JK. Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of I [kappa]B kinase and NF [kappa] B activation in macrophages. Biochem Pharmacol 2000; 60: 1665-1676.
71. Ishida J, Ohtsu H, Tachibana Y, et al. Antitumor Agents. Part 214:+ Synthesis and Evaluation of Curcumin Analogues as Cytotoxic Agents. Bioorg Med Chem 2002; 10: 3481-3487.
72. Artico M, Di Santo R, Costi R, et al. Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: synthesis, biological evaluation, and molecular modeling. J Med Chem 1998; 41: 3948-3960.
73. Adams BK, Ferstl EM, Davis MC, et al. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and antiangiogenesis agents. Bioorg Med Chem 2004; 12: 3871-3883.
74. Liang G, Li X, Chen L, et al. Synthesis and anti-inflammatory activities of mono-carbonyl analogues of curcumin. Bioorg Med Chem Lett 2008; 18: 1525-1529.
75. Anto RJ, Sukumaran K, Kuttan G, et al. Anticancer and antioxidant activity of synthetic chalcones and related compounds. Cancer Lett 1995; 97: 33-37.
76. Sardjiman SS, Reksohadiprodjo MS, Hakim L, Van der Goot H, Timmerman H. 1, 5-Diphenyl-1, 4-pentadiene-3-ones and cyclic analogues as antioxidative agents. Synthesis and structure-activity relationship. Eur J Med Chem 1997; 32: 625-630.
77. Dinkova-Kostova A, Abeygunawardana C, Talalay P. Chemoprotective Properties of Phenylpropenoids, Bis (benzylidene) cycloalkanones, and Related Michael Reaction Acceptors: Correlation of Potencies as Phase 2 Enzyme Inducers and Radical Scavengers. J Med Chem 1998; 41: 5287-5296.
78. Dinkova-Kostova A, Talalay P. Relation of structure of curcumin analogs to their potencies as inducers of Phase 2 detoxification enzymes. Carcinogenesis 1999; 20: 911-914.
79. El-Subbagh H, Abu-Zaid S, Mahran M, Badria F, Al-Obaid A. Synthesis and Biological Evaluation of Certain [alpha], [beta]-Unsaturated Ketones and Their Corresponding Fused Pyridines as Antiviral and Cytotoxic Agents. J Med Chem 2000; 43: 2915-2921.
80. Al-Omara M, Youssefa K, El-Sherbenya M, Awadallab S, El-Subbagha H. Synthesis and in vitro antioxidant activity of some new fused pyridine analogs. Arch Pharm (Weinheim) 2005; 338: 175-180.
81. Furness M, Robinson T, Ehlers T, et al. Antiangiogenic agents: studies on fumagillin and curcumin analogs. Curr Pharm Des 2005; 11: 357-373.
82. Robinson TP, Ehlers T, Hubbard I, et al. Design, synthesis, and biological evaluation of angiogenesis inhibitors: aromatic enone and dienone analogues of curcumin. Bioorg Med Chem Lett 2003; 13: 115-117.
83. Robinson TP, Hubbard RB, Ehlers TJ, et al. Synthesis and biological evaluation of aromatic enones related to curcumin. Bioorg Med Chem 2005; 13: 4007-4013.
84. Adams BK, Cai J, Armstrong J, et al. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redoxdependent mechanism. Anticancer Drugs 2005; 16: 263-275.
85. Gafner S, Lee S, Cuendet M, et al. Biologic evaluation of curcumin and structural derivatives in cancer chemoprevention model systems. Phytochemistry 2004; 65: 2849-2859.
86. Ligeret H, Barthelemy S, Zini R, et al. Effects of curcumin and curcumin derivatives on mitochondrial permeability transition pore. Free Radic Biol Med 2004; 36: 919-929.
87. Ligeret H, Barthélémy S, Bouchard Doulakas G, et al. Fluoride curcumin derivatives: new mitochondrial uncoupling agents. FEBS Lett 2004; 569: 37-42.
88. Youssef KM, El-Sherbeny MA, El-Shafie FS, et al. Synthesis of curcumin analogues as potential antioxidant, cancer chemopreventive agents. Arch Pharm (Weinheim) 2004; 337: 42-54.
89. Youssef K, El-Sherbeny M. Synthesis and antitumor activity of some curcumin analogs. Arch Pharm (Weinheim) 2005; 338: 181-189.
90. Youssef D, Nichols CE, Cameron TS, et al. Design, synthesis, and cytostatic activity of novel cyclic curcumin analogues. Bioorg Med Chem Lett 2007; 17: 5624-5669.
91. Youssef D, Potter E, Jha M, et al. Design, synthesis and bioevaluation of novel maleamic amino acid ester conjugates of 3, 5-bisarylmethylene-4-piperidones as cytostatic agents. Bioorg Med Chem Lett 2009; 19: 6364-6637.
92. Nichols C, Youssef D, Harris R, Jha A. Microwave-assisted synthesis of curcumin analogs. ARKIVOC 2006; 13: 64-72.
93. Weber WM, Hunsaker LA, Abcouwer SF, Deck LM, Vander Jagt DL. Anti-oxidant activities of curcumin and related enones. Bioorg Med Chem 2005; 13: 3811-3820.
94. Ohori H, Yamakoshi H, Tomizawa M, et al. Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol Cancer Ther 2006; 5: 2563-2571.
95. Weber WM, Hunsaker LA, Gonzales AM, et al. TPA-induced upregulation of activator protein-1 can be inhibited or enhanced by analogs of the natural product curcumin. Biochem Pharmacol 2006; 72: 928-940.
96. Singh S, Aggarwal BB. Activation of transcription factor NF-κB is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995; 270: 24995-5000.
97. Weber WM, Hunsaker LA, Roybal CN, et al. Activation of NFκB is inhibited by curcumin and related enones. Bioorg Med Chem 2006; 14: 2450-2461.
98. Chandru H, Sharada A, Bettadaiah B, et al. In vivo growth inhibitory and anti-angiogenic effects of synthetic novel dienonecyclopropoxy curcumin analogs on mouse Ehrlich ascites tumor. Bioorg Med Chem 2007; 15: 7696-7703.
99. Chandru H, Sharada A, Ananda Kumar C, Rangappa K. Antiangiogenic and growth inhibitory effects of synthetic novel 1, 5-diphenyl-1, 4 pentadiene-3-one-3-yl-ethanone pyridine curcumin analogues on Ehrlich ascites tumor in vivo. Med Chem Res 2008; 17: 515-529.
100. Jha A, Mukherjee C, Prasad AK, et al. E, E, E-1-(4-Arylamino-4-oxo-2-butenoyl)-3, 5-bis (arylidene)-4-piperidones: A topographical study of some novel potent cytotoxins. Bioorg Med Chem 2007; 15: 5854-5865.
101. Obach RS, Walsky RL, Venkatakrishnan K, Houston JB, Tremaine LM. In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 2005; 78: 582-592.
102. Appiah-Opong R, de Esch I, Commandeur JN, Andarini M, Vermeulen NP. Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur J Med Chem 2008; 43: 1621-1631.
103. Appiah-Opong R, Commandeur J, Istyastono E, Bogaards J, Vermeulen N. Inhibition of human glutathione S-transferases by curcumin and analogues. Xenobiotica 2009; 39: 302-311.
104. Das U, Alcorn J, Shrivastav A, et al. Design, synthesis and cytotoxic properties of novel 1- [4-(2-alkylaminoethoxy) phenylcarbonyl]-3, 5-bis (arylidene)-4-piperidones and related compounds. Eur J Med Chem 2007; 42: 71-80.
105. Das U, Das S, Bandy B, Stables JP, Dimmock JR. N-Aroyl-3, 5-bis (benzylidene)-4-piperidones: A novel class of antimycobacterial agents. Bioorg Med Chem 2008; 16: 3602-3607.
106. Sun A, Shoji M, Lu YJ, Liotta DC, Snyder JP. Synthesis of EF24-tripeptide chloromethyl ketone: a novel curcumin-related anticancer drug delivery system. J Med Chem 2006; 49: 3153-3158.
107. Sun A, Lu YJ, Hu H, et al. Curcumin analog cytotoxicity against breast cancer cells: exploitation of a redox-dependent mechanism. Bioorg Med Chem Lett 2009; 19: 6627-6631.
108. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996; 2: 209-215.
109. Um Y, Cho S, Woo HB, et al. Synthesis of curcumin mimics with multidrug resistance reversal activities. Bioorg Med Chem 2008; 16: 3608-3615.
110. Fuchs JR, Pandit B, Bhasin D, et al. Structure-activity relationship studies of curcumin analogues. Bioorg Med Chem Lett 2009; 19: 2065-2069.
111. Lee KH, Ab Aziz FH, Syahida A, et al. Synthesis and biological evaluation of curcumin-like diarylpentanoid analogues for antiinflammatory, antioxidant and anti-tyrosinase activities. Eur J Med Chem 2009; 44: 3195-3200.
112. Du Z, Liu R, Shao W, et al. α-Glucosidase inhibition of natural curcuminoids and curcumin analogs. Eur J Med Chem 2006; 41: 213-218.
113. Dimmock J, Padmanilayam M, Puthucode R, et al. A Conformational and Structure-Activity Relationship Study of Cytotoxic 3, 5-Bis (arylidene)-4-piperidones and Related NAcryloyl Analogues. J Med Chem 2001; 44: 586-593.
114. Dimmock J, Jha A, Zello G, et al. Cytotoxic N- [4-(3-aryl-3-oxo-1-propenyl) henylcarbonyl]-3, 5-bis (phenylmethylene)-4-piperidones and related compounds. Eur J Med Chem 2002; 37: 961-972.
115. Dimmock J, Das U, Gul H, et al. 3-Arylidene-1-(4-nitrophenylmethylene)-3, 4-dihydro-1H-naphthalen-2-ones and related compounds displaying selective toxicity and reversal of multidrug resistance in neoplastic cells. Bioorg Med Chem Lett 2005; 15: 1633-1636.
116. Singh RSP, Das U, Dimmock JR, Alcorn J. A general HPLC-UV method for the quantitative determination of curcumin analogues containing the 1, 5-diaryl-3-oxo-1, 4-pentadienyl pharmacophore in rat biomatrices. J Chromatogr B 2010; 878: 2796-2802.
117. Yadav B, Taurin S, Rosengren RJ, et al. Synthesis and cytotoxic potential of heterocyclic cyclohexanone analogues of curcumin. Bioorg Med Chem 2010; 18: 6701-7.
118. Quincoces Suarez JA, Rando DG, Santos RP, et al. New antitumoral agents I: In vitro anticancer activity and in vivo acute toxicity of synthetic 1, 5-bis (4-hydroxy-3-methoxyphenyl)-1, 4-pentadien-3-one and derivatives. Bioorg Med Chem 2010; 18: 6275-6281.
119. Yamakoshi H, Ohori H, Kudo C, et al. Structure-activity relationship of C5-curcuminoids and synthesis of their molecular probes thereof. Bioorg Med Chem 2010; 18: 1083-1092.
120. Changtam C, de Koning HP, Ibrahim H, et al. Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species. Eur J Med Chem 2010; 45: 941-956.
121. Makarov MV, Leonova ES, Rybalkina EY, et al. Synthesis, characterization and structure-activity relationship of novel Nphosphorylated E, E-3, 5-bis (thienylidene) piperid-4-ones. Eur J Med Chem 2010; 45: 992-1000.
122. Peng F, Tao Q, Wu X, et al. Cytotoxic, cytoprotective and antioxidant effects of isolated phenolic compounds from fresh ginger. Fitoterapia 2012; 83: 568-585.
123. Koivunen J, Aaltonen V, Peltonen J. Protein kinase C (PKC) family in cancer progression. Cancer Lett 2006; 235: 1-10.
124. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003; 23: 363-398.
125. Mamidi N, Gorai S, Sahoo J, Manna D. Alkyl cinnamates as regulator for the C1 domain of protein kinase C isoforms. Chem Phys Lipids 2012; 165: 320-330.
126. Katsori AM, Chatzopoulou M, Dimas K, et al. Curcumin analogues as possible anti-proliferative & anti-inflammatory agents. Eur J Med Chem 2011; 46 2722-2735.
127. Kasinski AL, Du Y, Thomas SL, et al. Inhibition of IαB kinasenuclear factor-αB signaling pathway by 3, 5-bis (2-flurobenzylidene) piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol 2008; 74: 654-661.
128. Olivera A, Moore TW, Hu F, et al. Inhibition of the NF-αB signaling pathway by the curcumin analog, 3, 5-Bis (2-pyridinylmethylidene)-4-piperidone (EF31): Anti-inflammatory and anti-cancer properties. Int ImmunoPharmacol 2012; 12: 368-377.
129. Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti- amyloidogenic effects for Alzheimer's βamyloid fibrils in vitro. J Neurosci Res 2004; 75: 742-750.
130. Chen SY, Chen Y, Li Y, et al. Design, synthesis, and biological evaluation of curcumin analogues as multifunctional agents for the treatment of Alzheimer's disease. Bioorg Med Chem 2011; 19: 5596-5604.
131. Ruan BF, Lu X, Li TT, et al. Synthesis, biological evaluation and molecular docking studies of resveratrol derivatives possessing curcumin moiety as potent antitubulin agents. Bioorg Med Chem 2012; 20: 1113-1121.
132. Thomas SL, Zhong D, Zhou W, et al. EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle 2008; 7: 2409-2417.
133. Thomas SL, Zhao J, Li Z, et al. Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategy. Biochem Pharmacol 2010; 80: 1309-1316.
134. Subramaniam D, May R, Sureban SM, et al. Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity. Cancer Res 2008; 68: 1962-1969.
135. Vilekar P, Awasthi S, Natarajan A, Anant S, Awasthi V. EF24 suppresses maturation and inflammatory response in dendritic cells. Int Immunol 2012: 24: 455-464.
136. Selvendiran K, Ahmed S, Dayton A, et al. Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenyl piperidones: differential cytotoxicity in healthy and cancer cells. Free Radic Biol Med 2010; 48: 1228-1235.
137. Selvendiran K, Tong L, Bratasz A, et al. Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts. Mol Cancer Ther 2010; 9: 1169-1179.
138. Dayton A, Selvendiran K, Kuppusamy ML, et al. Cellular uptake, retention and bioabsorption of HO-3867, a fluorinated curcumin analog with potential antitumor properties. Cancer Biol Ther 2010; 10: 1027-1032.
139. Zhao C, Yang J, Wang Y, et al. Synthesis of mono-carbonyl analogues of curcumin and their effects on inhibition of cytokine release in LPS-stimulated RAW 264.7 macrophages. Bioorg Med Chem 2010; 18: 2388-2393.
140. Wang Y, Yu C, Pan Y, et al. A Novel Synthetic Mono-Carbonyl Analogue of Curcumin, A13, Exhibits Anti-Inflammatory Effects In vivo by Inhibition of Inflammatory Mediators. Inflammation 2011; 35: 1-11.
141. Pan Y, Wang Y, Cai L, et al. Inhibition of high glucose-induced inflammatory response and macrophage infiltration by a novel curcumin derivative prevents renal injury in diabetic rats. Br J Pharmacol 2012; 166: 1169-1182.
142. Pan Y, Zhu G, Wang Y, et al. Attenuation of high-glucose-induced inflammatory response by a novel curcumin derivative B06 contributes to its protection from diabetic pathogenic changes in rat kidney and heart. J Nutr Biochem 2013; 24: 146-155.